Clinical Trial

Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD

Study acronym: LINE-AD
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 4, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a randomized, double-blind clinical trial of a daily oral dose of 200 mg emtricitabine vs. placebo in 35 participants with biomarker-confirmed MCI or mild to moderate dementia due to Alzheimer's disease. Study duration for each subject participating in the placebo-controlled research study will be approximately 12 months (up to a 3 months Screening Period, Baseline visit (1 month), 6 months of placebo or emtricitabine dosing, and 1 month follow-up). Participants will have up to 2 months to complete all procedures for the month 6 study visit.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2020-08-03; most recent amendment 2025-05-01.
Status change: Not Yet Recruiting → Recruiting 2021-12-21
Trial Details
NCT Number NCT04500847
Lead Sponsor Butler Hospital
Collaborators: Alzheimer's Association, Brown University, The Miriam Hospital, Cedars-Sinai Medical Center
Conditions Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Moderate Dementia
Enrollment 35 participants
Start Date 2021-12-17
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-04